Oxford BioMedica

Oxford BioMedica

Gene and cell therapy group focused on developing life changing treatments for serious diseases.

Oxford BioMedica is a publicly traded, gene and cell therapy group based in Oxford, Oxforshire, UK. The company and its subsidiaries (the "Group") have build a lentiviral delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products, both in-house and with partners. Its portfolio ranges across the areas of oncology, opthalmology, and CNS disorders.

Within its pipeline, Oxford BioMedica has several proprietary products, partnered products, and IP enabled and royalty bearing products. Its proprietary products, which would either be spun-out or licensed out, include:

  • OXB-202 - gene based treatment for corneal graft rejection. Phase 1/2 clinical studies are in preparation.
  • OXB-302 - gene based immunotherapy targeting a range of cancers. Pre-clinical studies are complete.
  • OXB-201 - gene therapy for wet AMD. Phase 1 clinical trials have been completed.
  • OXB-204 - in pre-clinical studies
  • OXB-208 - in pre-clinical studies
  • OXB-103 - in pre-clinical studies

The company's partnered products include:

  • AXO-LENTI-PD - gene therapy threatment for Parkinson's disease. Phase 1/2 clinical studies in preparation. Partnered with Axovant.
  • SAR 422459 - gene therapy for Stargardt disease. Phase 2 clinical studies ongoing. Licensed to Sanofi.
  • SAR 421869 - gene therapy for Usher syndrome type 1B. Phase 1/2a clinical trials ongoing. Licensed to Sanofi.

Additionally, Oxford BioMedica has multiple partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.

Timeline

People

Name
Role
LinkedIn

Andrew Heath

Deputy Chairman & Senior Independent Director

Dr. Lorenzo Tallarigo

Chairman

Heather Preston

Independent Non-Executive Director

Helen Stephenson-Ellis

Chief People Officer

James Miskin

Chief Technical Officer

Jason Slingsby

Chief Business Officer

John Dawson

CEO

Kyriacos Mitrophanous

Chief Scientific Officer

Lisa Giles

Chief Projects and Performance Officer

Martin Diggle

Non-Executive Director

Nick Page

COO

Stuart Henderson

Independent Non-Executive Director

Stuart Paynter

CFO

Further reading

Title
Author
Link
Type
Date

Oxford BioMedica announces further capacity expansion with new facility

Oxford BioMedica plc

Web

Oxford BioMedica to capture 25-30% of lentiviral vector market by 2026, predicts CTO

biopharma-reporter.com

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Michael Le Page, Clare Wilson, Jessica Hamzelou, Adam Vaughan, Conrad Quilty-Harper and Layal Liverpool
September 1, 2020
New Scientist
The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential information about the covid-19 pandemic
Reuters
September 1, 2020
@bsindia
AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmakers COVID-19 vaccine candidate
Ben Adams
June 8, 2020
FierceBiotech
Oxford Biomedica is currently most well known for its work on COVID-19 vaccines and its tie-up with AstraZeneca, but a much older deal sits with French Big Pharma Sanofi.
Reuters Editorial
June 1, 2020
IN
Britain's AstraZeneca has clinched expanded regulatory backing for two medications, including one for blockbuster cancer treatment Lynparza, in a development pipeline that now includes a possible coronavirus vaccine.
Reuters Editorial
May 28, 2020
IN
AstraZeneca has partnered with British cell therapy company Oxford Biomedica to make its experimental COVID-19 vaccine, as the drugmaker looks to bolster its manufacturing capacity to produce one billion doses.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.